Quarterly ResultMay 12, 2026, 07:12 AM
C4 Therapeutics Q1 Net Loss $25.1M; Revenue $6.15M
AI Summary
C4 Therapeutics reported a net loss of $25.1 million for the first quarter of 2026, an improvement from the $26.3 million net loss in the same period last year. Revenue from collaboration agreements was $6.15 million, down from $7.24 million year-over-year. The company ended the quarter with $268.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $25.1 million, compared to $26.3 million in Q1 2025.
- Revenue from collaboration agreements was $6.15 million in Q1 2026.
- Research and development expenses decreased to $24.6 million in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $268.3 million.
- Accumulated deficit reached $763.8 million as of March 31, 2026.
- Net loss per share was $0.20 for Q1 2026, down from $0.37 in Q1 2025.
- Achieved a $1.0 million discovery milestone under the MKDG agreement.
Price Impact
More from CCCC